Understand the source comparison
VIP Peptide: Dosing Methods Comparison
| Administration Route | Bioavailability | CNS Penetration | Onset Time | Primary Target Tissues | Practical Considerations | Professional Assessment ||—|—|—|—|—|—|| Subcutaneous Injection | 60–70% systemic | Minimal (<5%) | 5–10 minutes | Peripheral immune ce
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Administration Route | Bioavailability | CNS Penetration | Onset Time | Primary Target Tissues | Practical Considerations | Professional Assessment ||—|—|—|—|—|—|| Subcutaneous Injection | 60–70% systemic | Minimal (<5%) | 5–10 minutes | Peripheral immune cells, GI tract, systemic circulation | Requires sterile injection technique; higher systemic exposure; suitable for gut inflammation | Best for peripheral inflammatory conditions; ineffective for neuroinflammation || Intranasal Atomisation | 40–50% mucosal | High (direct olfactory transport) | 15–30 minutes | Hypothalamus, hippocampus, olfactory bulb, microglial cells | Requires mucosal atomisation device; technique-dependent; no injection needed | Superior choice for CNS inflammation, brain fog, microglial activation || Oral (not recommended) | <5% (enzymatic degradation) | None | N/A | None (degraded before absorption) | Peptide bonds cleaved by gastric acid and proteases | Ineffective. VIP is completely degraded in GI tract |